Physician profile
Tommy C Lu
NPI 1699795757
$3,106.44
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,469 · 2020: $372 · 2021: $123 · 2022: $143.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $814.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $723.20 | 2019-2020 | |
| Amarin Pharma, INC. | $433.36 | 2019 | |
| Abbvie INC. | $265.43 | 2021-2022 | |
| Gilead Sciences, INC. | $237.45 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $172.73 | 2019-2020 | |
| Amgen INC. | $125.00 | 2019 | |
| Radius Health, INC. | $124.99 | 2019 | |
| Portola Pharmaceuticals, LLC | $116.66 | 2019 | |
| Lilly USA, LLC | $92.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.